ReviewAntibiotics (Basel, Switzerland)2020
Development and Challenges of Antimicrobial Peptides for Therapeutic Applications.
Review in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 269 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
269 citing papers in PubMed, 583 citations in OpenAlex.
- Nano-antimicrobial peptides (Nano-AMPs) to combat resistant gram-negative bacteria.Drug delivery and translational research · 2026Review
- Peptide-Enabled Nanoplatforms for Malaria and Leishmaniasis: From Intracellular Targeting to Translational Diagnostic Perspectives.ChemMedChem · 2026Review
- Toward Chromatography-Free Convergent Peptide Synthesis via Nanostar Sieving.Organic process research & development · 2026Article
- Animal-Derived Antimicrobial Peptides: Emerging Therapeutic Strategies against Multidrug-Resistant Pathogens.Probiotics and antimicrobial proteins · 2026Review
- Anticancer Potential of Antimicrobial Peptides: Mechanisms, Clinical Application, Challenges, and Future Prospects.Drug development research · 2026Review
- Adaptive Response ofAntibiotics (Basel, Switzerland) · 2026Article
- A Novel Antimicrobial Peptide Displaying Broad-Spectrum Activity Against Pan-Resistant Pathogens and Low Propensity for Resistance Development.Antibiotics (Basel, Switzerland) · 2026Article
- Combating Antimicrobial Resistance with Hydrophilic and Eco-Friendly Membrane-Active Antibiotics Derived from Biological Nanoparticles.ACS nanoscience Au · 2026Article
- Chemical Optimization of Temporin A-L Peptides: From Native Isoforms to Enhanced Antimicrobial Analogs.ChemMedChem · 2026Review
- Nature-inspired biomaterial innovations to counter medical device-associated infections.Biomaterials science · 2026Review
- Bilayer Permeabilization and the 'Sand-in-a-Gearbox' Mechanism for Membrane-Active Molecules: Which Is Which?Antibiotics (Basel, Switzerland) · 2026Article
- Genome-Guided Discovery of an Antimicrobial Peptide Scaffold from an Undescribed AntarcticInternational journal of molecular sciences · 2026Article
- Antimicrobial Resistance as a Global Public Health Challenge: Epidemiological Burden, Bioethical Dimensions and Emerging Therapeutic Strategies.Infectious disease reports · 2026Review
- Cooperative membrane association as a mechanistic origin of synergistic antimicrobial peptide activity.RSC chemical biology · 2026Review
- Plant-Derived Peptide-Polymer Therapeutics for Cutaneous Infections and Inflammation: Mechanistic Basis, Delivery Design and Translational Considerations.Pharmaceutics · 2026Review
- Engineering host‑defense peptides enhanced by artificial intelligence and nano delivery systems to overcome biofilms and antimicrobial resistance.Engineering microbiology · 2026Review
- Pharmaceutical Peptides: From Synthesis and Mechanistic Pharmacology to Future Biologic Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Enhanced proteolytic stability and distinct mechanisms of a D-amino acid-modified antimicrobial peptide against Pseudomonas aeruginosa.Scientific reports · 2026Article
- MAPLE: interpretable deep learning identifies selective antimicrobial peptides using joint evolutionary-physicochemical analysis.Briefings in bioinformatics · 2026Article
- Peptides as a Therapeutic Alternative Against Leishmaniasis: A Scoping Review.Chemical biology & drug design · 2026Article
209 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
More than 3000 antimicrobial peptides (AMPs) have been discovered, seven of which have been approved by the U.S. Food and Drug Administration (FDA). Now commercialized, these seven peptides have mostly been utilized for topical medications, though some have been injected into the body to treat severe bacterial infections. To understand the translational potential for AMPs, we analyzed FDA-approved drugs in the FDA drug database. We examined their physicochemical properties, secondary structures, and mechanisms of action, and compared them with the peptides in the AMP database. All FDA-approved AMPs were discovered in Gram-positive soil bacteria, and 98% of known AMPs also come from natural sources (skin secretions of frogs and toxins from different species). However, AMPs can have undesirable properties as drugs, including instability and toxicity. Thus, the design and construction of effective AMPs require an understanding of the mechanisms of known peptides and their effects on the human body. This review provides an overview to guide the development of AMPs that can potentially be used as antimicrobial drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.